ATLANTA, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer of Alimera, will present new, real-world data on ILUVIEN at the Ophthalmology Innovation Summit (OIS) to be held Thursday, August 10, 2017 in conjunction with the 35th Annual Scientific Meeting of the American Society of Retinal Specialists (ASRS) in Boston.  Mr. Myers will be speaking as part of the Retina Public Company Showcase scheduled for 9:00 to 9:36 a.m.

The slides used in Mr. Myers’ presentation will be posted on the Alimera’s website,, prior to the meeting.

OIS unites industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs. At OIS@ASRS, Mr. Myers will present real-world data from the USER (U.S. Retrospective Chart Review in Patients Receiving ILUVIEN®) Study. USER is reporting 160 eyes in 130 patients at four U.S. eye centers treated with ILUVIEN for diabetic macular edema. In addition, he will provide updates on Alimera's efforts to secure an ILUVIEN indication for posterior uveitis in Europe.

"OIS fosters collaboration and innovation, so it is particularly meaningful to be able to share our most recent real-world data on ILUVIEN at this meeting and to provide updates on our pursuit of a posterior uveitis indication in Europe," said Mr. Myers. "Our OIS colleagues have been supportive of our progress with ILUVIEN since the beginning, so it is exciting that they will be the first to hear the results of our U.S. study, which closely mirrors the results of our FAME™ clinical studies."


ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant indicated in the E.U. to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant with its continuous microdosing is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months, enabling the physician to treat the disease consistently every day.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research, and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit

For press inquiries:
Katie Brazel
for Alimera Sciences 

For investor inquiries:
CG Capital
for Alimera Sciences

Primary Logo